Separate names with a comma.
Summary of the Neuroscience Innovation Panel Discussion The conference panel, featuring executives and scientists from leading psychedelic drug...
Future of Psychedelics Panel @ Sachs_NIF [MEDIA]
MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder...
LD-2 Disclosure Form - MindMed Lobbying on Health & Wellness issues in DC...
Here is a detailed comparison of the MindMed presentations from December 2024 and January 2025, focusing on updates and new content across various...
Breaking the Stigma with Advancements in Psychedelics https://cdn.jwplayer.com/previews/huVFJPCq
Defying Industry Setbacks, MindMed Advances Psychedelic To Phase 3...
Phase 3 Trial of MM120 for Generalized Anxiety Disorder (VOYAGE) - Trial Page...
Woman free of anxiety meds 1 year after Cleveland Clinic LSD trial success...
Psychedelic Stock MindMed: Investor Anticipation Rising | TDR Small Cap Sunday [MEDIA]
Docket Number: FDA-2023-D-1987: Psychedelic Drugs: Considerations for Clinical Investigations; Draft Guidance for Industry; Availability...
MindMed to Be Added to the Nasdaq Biotechnology Index https://www.businesswire.com/news/home/20241219955108/en/ Corporate Presentation December...
Back on track and going to 10.00 short term [IMG]
MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)...
Board Member - David Gryska added 2500 shares 12/5/2024 [IMG]
Psychedelic Clinical Trials: Regulatory Considerations from the FDA...
MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120...
MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy...
London Healthcare Week: As the company gears up for its first phase 3 trials, MindMed's CEO says he sees a tailwind of regulatory support for the...
New Association Launches to Expand Patient Access to Psychedelic Medicines...
